1. Home
  2. SACH vs PMVP Comparison

SACH vs PMVP Comparison

Compare SACH & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$0.84

Market Cap

57.5M

Sector

Real Estate

ML Signal

HOLD

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

HOLD

Current Price

$1.34

Market Cap

66.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SACH
PMVP
Founded
2010
2013
Country
United States
United States
Employees
27
N/A
Industry
Real Estate Investment Trusts
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.5M
66.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SACH
PMVP
Price
$0.84
$1.34
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
167.4K
352.1K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
19.23%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$145.00
N/A
Revenue Next Year
$6.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.83
$1.02
52 Week High
$1.45
$1.88

Technical Indicators

Market Signals
Indicator
SACH
PMVP
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
SACH
PMVP

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: